Synthetic Biologics is a bio-technology company, concentrating on the development of biologics for the prevention and treatment of infectious diseases and serious illness. The company is currently in Phase II testing with the product Trimesta for the treatment of cognitive dysfunction and relapse in Multiple Sclerosis. The company is in the preclinical testing stages with the drug SYN-004 for the treatment of C.Difficile, and SYN-005 for the treatment of Pertussis. The company is headquartered in Rockville, Maryland.  For more information, visit the company’s Web site at www.syntheticbiologics.com